Sapna Kashyap
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sapna Kashyap has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Abha Mishra
School of Biochemical Engineering, Indian Institute of Technology, Banaras Hindu University, Varanasi -221005, India
1 shared publicationAmit Singh
Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi -221005, India
1 shared publicationVikas Singh
Department of Chemical Engineering, Indian Institute of Technology-Delhi, New Delhi- 110016, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 14 (2) , 93-106
Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles
Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failure, cirrhosis of the liver, renal disease, including the nephrotic syndrome and hypertension. However, in ascites, it is clinically limited due to its frequent dosing and short biological half-life and its prolonged-release preparations are not available. Therefore, the main objective behind the present research work is to develop chitosan coated and conjugated poly (lactic-co-glycolic acid) (PLGA) nanocarriers, to sustain the delivery of FSM with improved systemic circulation. Emulsion-solvent evaporation technique was used for the preparation of nanoparticles. In-vivo pharmacokinetic study showed 2.6, 3.10, and 4.30 folds enhancement in relative availability of FSM for FSM-PLGA, FSM-chitosan-coated-PLGA and FSM-chitosan-conjugated- PLGA nanoparticles, respectively than FSM. The present research work concluded that FSM loaded chitosan conjugated PLGA nanoparticles could enhance the systemic circulation of FSM with improved pharmacokinetics parameters.
- 1 January 2019
- Published by Medknow in Research in Pharmaceutical Sciences
- Vol. 14 (2) , 93-106
Open AccessEnhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles
Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failure, cirrhosis of the liver, renal disease, including the nephrotic syndrome and hypertension. However, in ascites, it is clinically limited due to its frequent dosing and short biological half-life and its prolonged-release preparations are not available. Therefore, the main objective behind the present research work is to develop chitosan coated and conjugated poly (lactic-co-glycolic acid) (PLGA) nanocarriers, to sustain the delivery of FSM with improved systemic circulation. Emulsion-solvent evaporation technique was used for the preparation of nanoparticles. In-vivo pharmacokinetic study showed 2.6, 3.10, and 4.30 folds enhancement in relative availability of FSM for FSM-PLGA, FSM-chitosan-coated-PLGA and FSM-chitosan-conjugated- PLGA nanoparticles, respectively than FSM. The present research work concluded that FSM loaded chitosan conjugated PLGA nanoparticles could enhance the systemic circulation of FSM with improved pharmacokinetics parameters.